Brookline Capital Management Predicts Immunic Q1 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Brookline Capital Management issued their Q1 2026 earnings per share estimates for Immunic in a note issued to investors on Tuesday, November 18th. Brookline Capital Management analyst T. Bussian expects that the company will earn ($0.13) per share for the quarter. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Brookline Capital Management also issued estimates for Immunic’s Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.46) EPS.

Several other equities analysts also recently commented on IMUX. Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a report on Wednesday, October 8th. D. Boral Capital lowered their target price on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. HC Wainwright dropped their price target on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Finally, Roth Capital started coverage on Immunic in a research report on Friday, November 7th. They set a “buy” rating and a $3.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $7.40.

Immunic Price Performance

IMUX stock opened at $0.69 on Thursday. Immunic has a fifty-two week low of $0.56 and a fifty-two week high of $1.42. The stock has a market capitalization of $82.56 million, a price-to-earnings ratio of -0.73 and a beta of 1.53. The business’s fifty day moving average price is $0.82 and its two-hundred day moving average price is $0.85.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05.

Hedge Funds Weigh In On Immunic

A number of institutional investors have recently modified their holdings of the business. Qube Research & Technologies Ltd bought a new stake in shares of Immunic during the 3rd quarter worth $29,000. Millennium Management LLC raised its stake in Immunic by 414.5% during the third quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock worth $468,000 after acquiring an additional 427,361 shares in the last quarter. Focus Partners Wealth lifted its holdings in shares of Immunic by 1.5% in the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after acquiring an additional 39,063 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Immunic in the third quarter worth about $99,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Immunic in the 3rd quarter valued at approximately $52,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.